

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Title page:

The Change in Seroprevalence in the US plus Puerto Rico between May and September of SARS-CoV-2 Antibody in the Asymptomatic Population

Robert L. Stout, PhD and Steven J. Rigatti, MD
Clinical Reference Laboratory, Inc.
8433 Quivira Rd Lenexa, KS 66215

19 Objective: Determine the seroprevalence and 3 month temporal change of SARS-
20 COV-2 in the US and Puerto Rico in an asymptomatic well population.

21
22 Results: The prevalence of SARS-CoV-2 in the asymptomatic population has
23 doubled during the May to September time period, going from 3.0% to 6.6%.
24 Positive serology to SARS-COV-2 was similar in males and females but varies by
25 age. The greatest increase was in the youngest population. Based on the
26 September prevalence it is estimated that there are 11.1 million (bootstrap 95% CI:
27 10.8 – 11.5 million) asymptomatic SARS-CoV-2 infections in the US, which is 1.95
28 times the cumulative number of cases in the US reported to the CDC as of
29 September 1, 2020.

30 .

31 Conclusions: The number of new SARS-COV-2 cases more than doubled in this 3

32 months period. The seroprevalence by age group is high in the youngest (<20,
33 7.8%) and low in the oldest (> 70, 2.0%). Over the three month study period the rate
34 of increase in prevalence for SARS-COV-2 serology varies by state with a range
35 from 0.84 (State of New York) to more than 12 (Tennessee). This study identifies
36 states where public health mitigation has blunted the spread and also areas where
37 additional levels of intensified public education, surveillance and targeted
38 intervention may be warranted.

39 Manuscript

40 **Title: The Change in Seroprevalence between May and September of SARS-**
41 **CoV-2 Antibody in an Asymptomatic Population**

42

43 Objective: Determine the rate of change in prevalence of SARS-COV-2 antibody in
44 a self-reported asymptomatic well population over a three month period.

45

46 Method: Between 12 May and 25 September we examined SARS-COV-2 antibody
47 results on 113,369 consecutive life insurance applicants who were having blood
48 drawn for the purpose of underwriting mortality risk.

49

50 Results: In May the seroprevalence of SARS-CoV-2 was 3.0%(547/18,441),
51 3.1%(981/31,822) in June and 6.6%(4180/63,103) in September. Positive serology
52 to SARS-COV-2 was similar in males and females but varies by age. Geographical
53 distribution revealed a very high level of variation between states. Using 2019 US
54 Census state population data to adjust state specific rates of positivity, it is
55 estimated that the September level of seropositivity would correspond to 11.1
56 million asymptomatic SARS-CoV-2 infections in the US, which is roughly 2 times the
57 cumulative number of cases in the US reported to the CDC as of September 1,
58 2020.

59

60 Conclusions: The prevalence of positive SARS-COV-2 serology increased more
61 than 2 fold during the three month period from May to September 2020 going from
62 3.0% to 6.6%. During this period state specific rates of increase in prevalence vary
63 wildly from 0.8(New York) to more than 12 fold (Tennessee). The estimated number
64 of total SARS-CoV-2 infections based on positive serology is substantially higher
65 than the total number of cases reported to the CDC. This study identifies states
66 where public health mitigation has blunted the spread and also areas where
67 additional levels of intensified public education, surveillance and targeted
68 intervention may be warranted.

69 Introduction

70 In early 2020 a novel coronavirus emerged in Hubei Province, China¹. The
71 causative agent was a betacoronavirus most closely related genetically to zoonotic
72 viruses found in bats, and clinically similar to recent emergent epidemic
73 coronaviruses which caused Severe Acute Respiratory Syndrome (SARS) and
74 Middle Eastern Respiratory Syndrome (MERS)². Since then, the virus has
75 become a worldwide pandemic, infecting over 37 million persons and causing more
76 than 1 million deaths as of this writing³. The first case in the United States occurred
77 on January 20th, 2020⁴. And since then the Centers for Disease Control and
78 Prevention has recommended that all states report laboratory-confirmed cases⁵.
79 Case counts have been closely tracked by the CDC, the press, and academic
80 institutions. However, because the illness caused by SARS-CoV-2 may be
81 asymptomatic or minimally symptomatic⁶, these counts of cases may underestimate
82 the number of persons who have been infected. Various studies of seroprevalence
83 in the United States^{7,8} have shown different results based on timing and locality, but
84 have been consistent in showing that seroprevalence is higher than would be
85 implied by simple case counts based on viral antibody testing.

86

87 Because SARS-CoV-2 is novel, the presence of antibodies in the blood likely
88 indicates a history of infection since the pandemic began, and serologic testing can
89 be used to estimate the overall rate of infection, even in those who had minimal
90 symptoms or who were never tested despite symptoms.

91

92 In this study, a convenience sample of blood specimens submitted to a commercial
93 laboratory was used to conduct a survey of seroprevalence over a three month
94 study period. The goal was to estimate the seroprevalence and overall rate of
95 increase or decrease in positivity nationally and state by state.

96 Method: In the United States, the process of purchasing life insurance often
97 involves a brief physical examination by paramedical professionals, the collection of
98 height, weight and blood pressure measurements, and the testing of blood and
99 urine specimens for common laboratory test related to overall health. Such tests are
100 seldom, if ever, performed on individuals below age 16 years or above 85 years.

101 Between May12th and September 25, 2020, 113,369 consecutive individuals were
102 tested for antibodies to SARS-CoV-2. Individuals were part of a convenience
103 sample from a pool of life insurance applicants who had blood tests performed as
104 part of life insurance underwriting. This sample represents approximately one fifth of
105 all samples tested at the facility during that time. All applicants self-reported that
106 they were well at the time of application. The antibody tests were performed using
107 the Roche Elecsys Anti-SARS-CoV-2 kit on the Roche e602 analyzer, with a stated
108 sensitivity of 100% and specificity of 99.8%. Other information available on test
109 subjects included state of residence, age and sex.

110 The differences in continuous variables between the antibody-positive and negative
111 groups were tested for significance with the Mann-Whitney U test, while differences
112 in categorical variables were tested using the chi-square test. All statistical
113 analyses were performed using R (version 3.6.1)⁹ and R-studio (version1.2.1335)¹⁰.

114
115 To estimate the total burden of SARS-CoV-2 infections in the US the total 2019
116 estimated census population was multiplied by the US population proportion
117 between the ages of 16 and 80 (75.5%). Then, the state-specific proportion of
118 positive tests was applied from our sample. Confidence limits were estimated by
119 generating 5000 bootstrap samples (with replacement) of our data and recalculating
120 the total number of US cases. Under and over-representation of states was
121 determined by a ratio between the proportion of individuals living in a given state to
122 the proportion of tests performed in that state.

123

124 Results

125 The overall sample included 113,369 individuals with a median age of 42 years
126 (IQR: 33-54), 55.5% of whom were male. Geographical distribution deviated

127 somewhat from the overall population distribution of the US, with some under-
128 representation from Maine, West Virginia, Vermont and Oklahoma, and over-
129 representation from Nebraska, Hawaii, and Utah. Characteristics of the study
130 population are displayed in Table 1. The antibody positive group tended to be
131 slightly younger (median age 41) vs. the antibody negative group (median age 42).
132 The distribution by decade of age is displayed in Table 2. This study estimated the
133 seroprevalence of SARS-CoV-2 antibodies in a geographically diverse sample of
134 adults in the US within a 3-month collection period ending the 25th of September
135 2020. The rate of positivity ranged from 0% to 14.7% by state and from 2-7.8%
136 across age, displayed in Figure 1. While slightly more females were positive the
137 difference is not statistically significant. The choropleth map of seropositivity roughly
138 corresponds to the areas where the most SARS-COV-2 cases were reported during
139 this period of time displayed in Figure 2. Our results suggest that many more
140 infections occurred than were reported. This is likely due to asymptomatic or
141 minimally symptomatic infections for which care was not sought or symptomatic
142 infection for which testing was not available or obtained.

143

144 Various studies have been published, both before and after peer review, which have
145 reported seroprevalence of SARS-CoV-2 antibodies in the US. Most notably,
146 Havers et al¹¹. evaluated a convenience sample (n=16,025) of serological tests on
147 sera submitted to 2 commercial laboratories from 10 US regions. Their estimates of
148 seroprevalence ranged from 1% to 7%, with the highest rates occurring in the New
149 York City metro area, Louisiana and Connecticut. The timeframe of this testing
150 differed by region and was earlier than the current study. The authors
151 estimated that the seroprevalence implied that between 6 and 24 times the number
152 of infections had occurred in the studied regions than had been reported.

153

154 Stadlbauer et al reported on longitudinal changes in seroprevalence in New York
155 City between late February and mid-April 2020¹². Over this period of time
156 seroprevalence increased from 2.2% to 10.1%. Rosenberg et al also reported on
157 seroprevalence in the New York metro area¹³.

158 The collection period was from April 19 to 28, 2020, and the estimate was 22.7%.
159 The higher estimate than the current study, despite being performed in an earlier
160 time period, is likely due to a geographical distribution that is more localized to the
161 highest prevalence metro region, rather than the entire state of New York.
162 We report that, around the time of study, the number of infections in the US was
163 nearly 2 times higher than cases of infection reported suggesting a much more
164 widespread pandemic, but with a smaller rate of hospitalization, complications and
165 deaths. Weaknesses of the study include the imbalanced representation of the US
166 states, as well as the lack of samples from those under age 16 or over age 80. The
167 age distribution is also more heavily weighted to the young adult years, which is not
168 representative of the US population. Although the sample size was large, it was not
169 large enough to stratify by both age and geography when estimating population
170 seroprevalence. Finally, the life insurance-buying population tends to be both
171 healthier and mid-income or wealthier than average, and this could also bias the
172 results in an indeterminate direction. Even with these stated limitations the study
173 validates the need for population wide surveillance; it is in keeping with the AJPH
174 editor on Accurate Statistics on COVID-19 Are Essential for Policy Guidance and
175 Decisions¹⁴ clearly define the need for population wide seroprevalence surveys to
176 collect the information necessary for sound national and public health policy
177 decisions.

178

179

180 Conclusion

181 The rate of SARS-CoV-2 seropositivity in this population of self-reported well
182 insurance applicants implies a burden of infection approximately 2 times higher than
183 the number of reported cases. State specific rates of increase identify regions where
184 public health mitigation strategies are working and areas where additional effort or
185 changes in strategies are required. First public education must be intensified in
186 regions where the rate of increase is the highest; the temporal prevalence data
187 presented in this report should provide the “facts to support” these changes.

188

189 Both authors contributed equally to the development of this data, the statistical
190 analysis, writing and review of this article. We wish to extend a special thanks to Dr
191 Michael Fulks for reviewing and providing valuable suggests for this article.

192

193 Western IRB reviewed the study under the Common Rule and applicable guidance
194 and determined it is exempt under 45 CFR § 46.104(d)(4) using de-identified study
195 samples for epidemiologic investigation.

196

197

198 REFERENCES

199 1 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of
200 patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* (London,
201 England) 395:497–506

202 2 de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS:
203 recent insights into emerging coronaviruses. *Nat Rev Microbiol* 14:523–534

204 3 Max Roser, Hannah Ritchie, Esteban Ortiz-Ospina and Joe Hasell (2020) -
205 "Coronavirus Pandemic (SARS-COV-2)". Published online at OurWorldInData.org.
206 Retrieved from: '<https://ourworldindata.org/coronavirus>' [Online Resource]

207 4 Harcourt J, Tamin A, Lu X, et al. Severe acute respiratory syndrome coronavirus 2
208 from a patient with coronavirus disease, United States. *Emerg Infect Dis*.
209 2020;26(6):1266-1273.doi:10.3201/eid2606.200516

210 5 Nationally Notifiable Diseases Surveillance System. Coronavirus disease 2019
211 (SARS-COV-2). Accessed July 29, 2020.

212 <https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-SARS-CoV-2/>

213 6 The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team.
214 The Epidemiological Characteristics of an Outbreak fo 2019 Novel Coronavirus
215 Diseases (SARS-COV-2)-China, 2020. *China CDC Weekly*. 2020;2:113-22.

216 7 Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population Point Prevalence of
217 SARS-CoV-2 Infection Based on a Statewide Random Sample — Indiana, April 25–
218 29, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:960-964.

219 DOI: <http://dx.doi.org/10.15585/mmwr.mm6929e1external>

220 8 Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2–specific
221 antibodies among adults in Los Angeles County, California. JAMA 2020;323:2425–
222 7.

223 9 R Core Team (2019). R: A language and environment for statistical computing. R
224 Foundation for Statistical Computing, Vienna, Austria. URL [https://www.R-](https://www.R-project.org/)
225 [project.org/](https://www.R-project.org/).

226 10 Studio Team (2020). RStudio: Integrated Development for R. RStudio, PBC,
227 Boston, MA URL <http://www.rstudio.com/>.

228 11 Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2
229 in 10 Sites in the United States, March 23-May 12, 2020 [published online ahead of
230 print, 2020 Jul 21]. JAMA Intern Med.
231 2020;10.1001/jamainternmed.2020.4130. doi:10.1001/jamainternmed.2020.4130

232 12 Stadlbauer D, Tan J, Jiang K, et al. Seroconversion of a city: longitudinal
233 monitoring of SARS-CoV-2 seroprevalence in New York City. medRxiv. Preprint
234 posted online June 29, 2020. doi:10.1101/2020.06.28.20142190


235 13 Rosenberg ES, Tesoriero JM, Rosenthal EM, et al Cumulative incidence and
236 diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. Published online
237 June 17, 2020. doi:[10.1016/j.annepidem.2020.06.004](https://doi.org/10.1016/j.annepidem.2020.06.004)

238 14 Daniel Tarantola, Wendy E. Parmet, Michael C. Costanza and Stella Yu
239 AJPH.110(7), pp. 925–926


It is made available under a [CC-BY-NC 4.0 International license](https://creativecommons.org/licenses/by-nc/4.0/) .

Figure 1

SARS-CoV-2 Seroprevalence - June



SARS-CoV-2 Seroprevalence - September



Tables 1-3

Table 1: Characteristics of study population by SARS-CoV-2 antibody status. Numeric values shown as median [IQR].
1 p-value by Pearson Chi-square test.

	SARS-CoV-2 negative n = 106,551	SARS-CoV-2 positive n = 5,623	p
Age (yrs)	42 [34,54]	41 [33,52]	0.000 ¹
18-40	45.6%	52.2%	
41-60	41.1%	39.9%	
61-85	13.3%	7.9%	
Sex, (% male)	55.6%	53.3%	0.002 ¹

Table 2. Sera positivity for SARS-COV-2 by age

	NON (106,551)	REA(5623)	Total
<= 20	1127(92.2%)	95 (7.8%)	1222
21 - 30	16112 (93.3%)	1155 (6.7%)	17267
31 - 40	31219 (94.9%)	1680 (5.1%)	32899
41 - 50	24133 (94.9%)	1305 (5.1%)	25438
51 - 60	19621 (95.4%)	937 (4.6%)	20558
61 - 70	12104 (96.8%)	404 (3.2%)	12508
71+	2049 (98.0%)	41 (2.0%)	2090
NO AGE	1296(93.4%)	91(6.6%)	1387
Total	106365 (95.0%)	5617 (5.0%)	113,369

Table 3: Seroprevalence for September and the rate of increase in prevalence from May to September by state.

STATE	Sept%	RATIO	STATE	Sept%	RATIO	STATE	Sept%	RATIO
NY	14.4	0.8	IN	5.2	2.6	NV	10.1	4.2
RI	3.7	0.9	GA	7.8	2.7	MS	9.3	4.4
MA	4.1	1.0	NC	3.1	3.0	FL	9.3	4.8
CT	5.9	1.0	SD	6.5	3.0	KS	8.2	5.1
NJ	9.5	1.0	CA	4.5	3.0	UT	3.6	5.1
DC	6.4	1.2	LA	11.9	3.0	AL	7.9	5.5
MI	5.5	1.3	IA	5.2	3.1	PR	3.9	5.6
PA	3.9	1.5	CO	4.1	3.1	OH	5.0	5.8
MD	6.2	1.5	MO	6.3	3.4	AZ	7.5	6.3
IL	5.7	1.6	KY	3.5	3.5	SC	6.6	6.4
MN	3.8	1.7	WA	4.1	3.5	TX	8.0	6.9
NE	4.2	2.0	AR	4.9	3.5	ID	5.8	8.1
DE	7.1	2.2	WI	4.8	3.7	OK	5.5	10.7
			VA	4.5	3.8	TN	6.8	12.9

September % is number of positives by state. Ratio is the September prevalence divided by the combined prevalence from May and June. The states of AK, ME, WY, VT, MT, ND, WV, NM, HI, and NH with fewer than 10 positives each were excluded from this analysis. Combined they have 45/3,319 (1.43%) positives.

